You are here: Industry Insights > AstraZeneca

News List

US enters agreement for experimental prophylactic COVID-19 antibody cocktail europeanpharmaceuticalreview
October 15, 2020
The US government will develop and manufacture AstraZeneca’s investigational monoclonal antibody cocktail, AZD7442, a potential prophylactic treatment for COVID-19.
COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials worldpharmanews
October 14, 2020
AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the this weeks.
AstraZeneca secures $486m from US for Covid-19 antibody pharmaceutical-technology
October 14, 2020
AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment.
US, AstraZeneca sign pact for COVID-19 antibody treatment used to treat Trump expresspharma
October 12, 2020
The agreement, under Operation Warp Speed, is to develop a monoclonal antibody cocktail that can prevent COVID-19, especially in high-risk population.
Clinical trials of AstraZeneca-Oxford COVID-19 vaccine candidate resumes in UK expresspharma
September 24, 2020
This is following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval pharmatimes
September 23, 2020
GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
Statement on AstraZeneca Oxford SARS-CoV-2 Vaccine, AZD1222, COVID-19 Vaccine Trials Temporary Pause drugs.com
September 23, 2020
As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222...
Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply prnasia
September 22, 2020
Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as...
Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer pharmatimes
September 22, 2020
AstraZeneca and MSD’s (Merck) PARP inhibitor Lynparza has demonstrated long-term progression-free survival (PFS) benefit in BRCA-mutated advanced ovarian cancer.
Thermo Fisher Scientific, AstraZeneca to Collaborate on Biomarker Discovery americanpharmaceuticalreview
September 21, 2020
Thermo Fisher Scientific announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page